RxDoctor Payments Data

Madhavi Pesari, MD

Internal Medicine · Mesa, AZNPI 1528047891

Payments from drug & device makers

$2,329in general payments, 2019–2025

Across 128 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$539
  • Boehringer Ingelheim$378
  • Lilly USA, LLC$183
  • Astellas Pharma US Inc$169
  • Sumitomo Pharma America, Inc.$133
  • Novartis$99
  • plus $828 from 16 others

What the payments were for

  • Food & beverage$2,23096%
  • Education$994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,329 in reported general payments places this provider in the 85th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$270,496
Medicare patients
433
Services billed
2,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$138,047
JardianceEmpagliflozin52$80,803
EliquisApixaban59$77,027
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$56,233
MounjaroTirzepatide37$46,337
MyrbetriqMirabegron35$44,913
FarxigaDapagliflozin Propanediol30$34,329
GemtesaVibegron22$26,789
XareltoRivaroxaban29$20,126
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$15,898
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$10,043
Repatha SureclickEvolocumab11$7,719
Breo ElliptaFluticasone/Vilanterol13$5,317
Levothyroxine Sodium506$4,558
Atorvastatin Calcium382$4,261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$99$138,047102 claims
Boehringer IngelheimJardiance$378$80,80352 claims
PfizerEliquis$58$77,02759 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$539$71,59362 claims
Lilly USA, LLCMounjaro$183$46,33737 claims
Astellas Pharma US IncMyrbetriq$169$44,91335 claims
AstraZenecaFarxiga, Symbicort$73$37,48844 claims
Sumitomo Pharma America, Inc.Gemtesa$133$26,78922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →